Steven Kempers, MD
Dermatology · Fridley, MNNPI 1003852427
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,833 of the $15,602 with a category attached, or 69.4%. 12 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 50.2% of the total. Reporting peaked in 2023 at $8,089 and has fallen 69.1% since, to $2,500 in 2025. Among dermatology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 37 payments — averaging $421.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$8K
- Incyte Corporation$5K
- VYNE Pharmaceuticals Inc.$2K
- Novartis$435
- Johnson & Johnson$399
- Janssen Research & Development, LLC$89
- plus $190 from 6 others
Across 741 payments — averaging $6921.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$761K
- Novartis$655K
- AbbVie$632K
- Incyte Corporation$522K
- E.r. Squibb & Sons, L.L.C.$400K
- Janssen Research & Development, LLC$393K
- plus $1.8M from 16 others
What the payments were for
- Consulting fees$10,83369%
- Speaking & faculty fees$2,10013%
- Travel & lodging$1,4059%
- Food & beverage$1,2648%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 12 | $7,839 |
| Incyte Corporation | 6 | $4,550 |
| VYNE Pharmaceuticals Inc. | 1 | $2,100 |
| Novartis | 5 | $435 |
| Johnson & Johnson | 4 | $399 |
| Janssen Research & Development, LLC | 2 | $89 |
| LEO Pharma Inc. | 1 | $50 |
| Bausch Health US, LLC | 1 | $45 |
| Acrotech Biopharma Inc. | 1 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| Sanofi | 1 | $18 |
| Merck | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,602 in reported general payments places this provider in the 95th percentile of 273 dermatology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 29 | $290,449 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 11 | $70,464 |
| Fluocinonide | 11 | $522 |
| Triamcinolone Acetonide | 35 | $391 |
| Ketoconazole | 16 | $358 |
| Doxycycline Hyclate | 18 | $346 |
| Azithromycin | 20 | $15 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Fridley
- Bailey LeeFridley$977
- Kristina ShafferEagan$538K
- Margareth Pierre-LouisMinneapolis$439K
- Maria HordinskyMinneapolis$85K
- Afsaneh AlaviRochester$71K
- Todd SeelhammerSaint Paul$63K
- Brittney SchultzMinneapolis$52K
- David PearsonMinneapolis$46K
- Phillip EckerWayzata$31K
- Noah GoldfarbMinneapolis$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.